Patel Kunj, Peebles R Stokes
Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-2650, USA.
Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232-2650, USA.
Biomedicines. 2022 Nov 9;10(11):2862. doi: 10.3390/biomedicines10112862.
Prostacyclin is a metabolic product of the cyclooxygenase pathway that is constitutively expressed and can be induced during inflammatory conditions. While prostacyclin and its analogs have historically been considered effective vasodilators and used in treating pulmonary hypertension, prostacyclin has demonstrated potent anti-inflammatory effects in animal models of allergic airway inflammation. In vitro studies reveal that prostacyclin directly inhibits type 2 cytokine production from CD4+ Th2 cells and ILC2 and reduces the ability of dendritic cells to generate Th2 cytokine production from CD4+ T cells in an antigen-specific manner. Thus, there is strong evidence that prostacyclin may be an additional therapeutic target for treating allergic inflammation and asthma in human subjects.
前列环素是环氧化酶途径的一种代谢产物，它在正常情况下表达，并可在炎症状态下被诱导产生。虽然前列环素及其类似物在历史上一直被认为是有效的血管扩张剂，并用于治疗肺动脉高压，但前列环素在过敏性气道炎症的动物模型中已显示出强大的抗炎作用。体外研究表明，前列环素直接抑制CD4+ Th2细胞和2型固有淋巴细胞产生2型细胞因子，并以抗原特异性方式降低树突状细胞从CD4+ T细胞产生Th2细胞因子的能力。因此，有充分证据表明前列环素可能是治疗人类过敏性炎症和哮喘的另一个治疗靶点。
